Results 31 to 40 of about 36,039 (270)

An evidence-based practice in a patient with myelosuppression after chemotherapy and refused to take the medication (1例化疗后骨髓抑制拒绝药物干预患者的循证实践)

中西医结合护理, 2023
Objective To investigate the evidence-based Traditional Chinese Medicine(TCM) nursing interventions on myelosuppression after chemotherapy. Methods Through evidence-based nursing strategies, relevant literature on the improvement of myelosuppression ...
ZHANG Mi (张秘), JIANG Honglin (江虹霖), Mei Yuwei (梅雨薇), ZHANG Jie (张杰), HE Qing (何清)   +4 more
doaj   +1 more source

Chemotherapy induced myelosuppression

East African Medical Journal, 2007
To evaluate chemotherapy induced myelosuppression, its management and outcome.Retrospective analysis of patients aged 13 years and above.Hurlingham Oncology Clinic and the Nairobi Hospital during the period of June 1998 to June 2003.Two hundred and two solid tumour and lymphoma patients treated with pulsed chemotherapy at Hurlingham Oncology Clinic and
Othieno-Abinya, N. A., Waweru, A., Nyabola, L. O.   +2 more
openaire   +4 more sources

Hematologic Safety of Radium-223 Dichloride: Baseline Prognostic Factors Associated With Myelosuppression in the ALSYMPCA Trial. [PDF]

, 2016
BACKGROUND: Myelosuppression is common in patients with progressive castration-resistant prostate cancer and bone metastases. Radium-223 prolongs overall survival in these patients but may cause myelosuppression; understanding risk factors will improve ...
Nilsson, Sten, Coleman, RE, Michalski, Jeff M., Nilsson, S, Germino, Joseph, O'Sullivan, JM, Thuresson, M., Vogelzang, Nicholas J., Vogelzang, NJ, O\u27Sullivan, Joe M, Nilsson, S,, Nilsson, S., O'Sullivan, Joe M., Xu, L, Vogelzang, Nicholas J, Sartor, Oliver, Vogelzang, N.J., Xu, L., Sartor, O., Parker, C., Sartori, Oliver, O'Sullivan, J.M., Coleman, Robert E., Sartor, O, Michalski, JM, Coleman, R.E., Parker, Christopher, Thuresson, M, Michalski, J.M., Parker, C, Widmark, A, Widmark, A., Widmark, Anders,, O'Sullivan, Joe M; id_orcid, Coleman, Robert E, Widmark, Anders, Xu, Lei, Michalski, Jeff M, Thuresson, Marcus, Germino, J, Germino, J.   +40 more
core   +1 more source

In Vitro Myelosuppression and Immunosuppression by Ethanol [PDF]

Journal of Clinical Investigation, 1973
Concentrations of ethanol similar to those in the blood of intoxicated patients suppressed phytohemagglutinin- or streptolysin O-induced lymphocyte transformation, and inhibited bone marrow granulocyte colony growth in soft agar. Inhibition of lymphocyte transformation and granulocyte colony growth occurred despite the presence of large concentrations ...
G, Tisman, V, Herbert
openaire   +2 more sources

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

, 2002
PURPOSE: To develop a semimechanistic pharmacokinetic-pharmacodynamic model describing chemotherapy-induced myelosuppression through drug-specific parameters and system-related parameters, which are common to all drugs.
Karlsson, Mats O.,, Maas, Hugo, Nguyen, Laurent, Henningsson, Anja,, Henningsson, Anja, Friberg, Lena E.,   +5 more
core   +1 more source

Tyrosine kinase inhibitor and rituximab‐CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report

Clinical Case Reports, 2017
Key Clinical Message Non‐Hodgkin lymphoma can occur concurrently with chronic phase‐chronic myeloid leukemia (CML) at initial diagnosis. Combination treatment with second‐generation tyrosine kinase inhibitors and rituximab‐CHOP for patients newly ...
Yuki Takeyasu, Atsushi Satake, Yoshiko Azuma, Yukie Tsubokura, Hideaki Yoshimura, Masaaki Hotta, Takahisa Nakanishi, Shinya Fujita, Aya Nakaya, Tomoki Ito, Shosaku Nomura   +10 more
doaj   +1 more source

Predictors of Myelosuppression for Patients with Head and Neck Squamous Cell Carcinoma After Induction Chemotherapy

Clinical Medicine Insights: Oncology
Background: Induction chemotherapy (ICT) has become an initial treatment for head and neck squamous cell carcinoma (HNSCC). However, myelosuppression, an unavoidable side effect of ICT, significantly impacts follow-up treatment and prognosis.
Wen-qing Chen, Liang Peng, Xue-lan Zeng, Wei-ping Wen, Wei Sun   +4 more
doaj   +1 more source

Scaling the time-course of myelosuppression from rats to patients with a semi-physiological model

, 2010
AIM: To investigate the potential of a model for chemotherapy-induced myelosuppression to predict the full time-course of myelosuppression in patients based on rat data.
Karlsson, Mats O,, Friberg, Lena E,, Sandström, Marie,   +2 more
core   +1 more source

Diffuse MRI Edema Predicts Relapse in Cerebral Amyloid Angiopathy–Related Inflammation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To identify MRI predictors of relapse and quantify relapse and mortality risk in cerebral amyloid angiopathy–related inflammation (CAA‐RI). A secondary objective was to assess the association between mycophenolate mofetil use and relapse risk. Methods We performed a retrospective cohort study of 36 patients with CAA‐RI treated at the
G. Abbas Kharal, Gowtham Yerneni, Kim J. Griffin, Nicolas Thompson, Ken Uchino, Irene Katzan, Dolora Wisco, Abeer Farrag, Jayashree Sundarajan, Andrew Russman, M. Shazam Hussain   +10 more
wiley   +1 more source

GWAS study of myelosuppression among NSCLC patients receiving platinum-based combination chemotherapy

Acta Biochimica et Biophysica Sinica
Platinum-based chemotherapy remains the mainstay for non-small cell lung cancer (NSCLC), but it frequently causes dose-limiting myelosuppression, with significant individual variability in susceptibility.
Huang Hanxue, Liu Junyan, Xiao Qi, Mao Chenxue, She Lei, Yu Lulu, Yu Bing, Lei Mengrong, Gao Ying, He Baimei, Pan Pinhua, Li Xi, Yin Jiye, Liu Zhaoqian   +13 more
doaj   +1 more source